Leishmaniasis: Difference between revisions

(Text replacement - "==Diagnostic Evaluation==" to "==Evaluation==")
 
(5 intermediate revisions by 2 users not shown)
Line 1: Line 1:
==Background==
==Background==
[[File:Leishmaniasis life cycle diagram en.png|thumb|Life cycle]]
*Vector: sandfly
*Vector: sandfly
*Occurs sporadically in rural Africa, Asia, Mediterranean, Central/South America
*Occurs sporadically in rural Africa, Asia, Mediterranean, Central/South America
Line 6: Line 7:


==Clinical Features==
==Clinical Features==
[[File:Leishmaniasis ulcer.jpg|thumb|Cutaneous leishmaniasis ulcer]]
===Cutaneous===
===Cutaneous===
*Single to diffuse nodules/plagues with central clearing/eschar/fibrinous exudate
*Single to diffuse nodules/plagues with central clearing/eschar/fibrinous exudate
Line 14: Line 16:
===Visceral (Kala-azar)===
===Visceral (Kala-azar)===
*Darkening of skin, malaise, fever, weight lost, splenomegaly with advanced disease causing hepatic dysfunction, jaundice, ascites, thrombocytopenia, and hemorrhagic complications
*Darkening of skin, malaise, fever, weight lost, splenomegaly with advanced disease causing hepatic dysfunction, jaundice, ascites, thrombocytopenia, and hemorrhagic complications
**Anemia, neutropenia, thrombocytopenia, hypoalbuminemia, hyperbilirubinemia
**Anemia, neutropenia, [[thrombocytopenia]], [[hypoalbuminemia]], hyperbilirubinemia


==Differential Diagnosis==
==Differential Diagnosis==
Line 26: Line 28:
*Nocardia and actinomycosis
*Nocardia and actinomycosis
*Cutaneous [[tuberculosis]]
*Cutaneous [[tuberculosis]]
{{Travel Skin Conditions DDX}}


==Evaluation==
==Evaluation==
Line 39: Line 43:
**Topical [[Paromomycin]]
**Topical [[Paromomycin]]
**Local injection of Stibogluconate or Meglumine antimoniate  
**Local injection of Stibogluconate or Meglumine antimoniate  
**Debridement of necrotic tissue
*Complicated cutaneous leishmaniasis
*Complicated cutaneous leishmaniasis
**PO [[Fluconazole]] or Miltefosine.  
**PO [[Fluconazole]] or Miltefosine.  
Line 46: Line 51:


==Disposition==
==Disposition==
*
*Discharge with infectious disease followup


==See Also==
==See Also==

Latest revision as of 12:22, 12 December 2020

Background

Life cycle
  • Vector: sandfly
  • Occurs sporadically in rural Africa, Asia, Mediterranean, Central/South America
  • Wide variety of symptoms given numerous species of protozoa
  • 500,000 new cases and 60,000 deaths each year

Clinical Features

Cutaneous leishmaniasis ulcer

Cutaneous

  • Single to diffuse nodules/plagues with central clearing/eschar/fibrinous exudate

Mucocutaneous

  • Mucosal destruction, deformity nasal blockage, bleeding, increased secretions, sloughing of dead tissue, dysphonia, odynophagia, respiratory distress

Visceral (Kala-azar)

  • Darkening of skin, malaise, fever, weight lost, splenomegaly with advanced disease causing hepatic dysfunction, jaundice, ascites, thrombocytopenia, and hemorrhagic complications

Differential Diagnosis

  • Cutaneous/Mucocutaneous-bacterial skin infection
  • Malignancy
  • Sarcoidosis
  • Spider bite
  • Tropical ulcer
  • Yaws
  • Cutaneous anthrax
  • Nocardia and actinomycosis
  • Cutaneous tuberculosis

Travel-related skin conditions

See also domestic U.S. ectoparasites

Evaluation

  • CBC
  • Chem
  • Histology
  • Culture
  • Bone marrow or spleen biopsy (for visceral form)
  • PCR

Management

  • Uncomplicated cutaneous leishmaniasis
    • Topical Paromomycin
    • Local injection of Stibogluconate or Meglumine antimoniate
    • Debridement of necrotic tissue
  • Complicated cutaneous leishmaniasis
  • Visceral leishmaniasis

Disposition

  • Discharge with infectious disease followup

See Also

References